Ameritas Advisory Services LLC Purchases 3,830 Shares of AbbVie Inc. $ABBV

Ameritas Advisory Services LLC grew its position in AbbVie Inc. (NYSE:ABBV) by 30.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,271 shares of the company’s stock after purchasing an additional 3,830 shares during the quarter. Ameritas Advisory Services LLC’s holdings in AbbVie were worth $3,767,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the 2nd quarter worth about $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie during the second quarter worth approximately $28,000. Financial Gravity Companies Inc. bought a new stake in AbbVie in the second quarter worth approximately $36,000. Delos Wealth Advisors LLC bought a new stake in AbbVie in the second quarter worth approximately $39,000. Finally, Abich Financial Wealth Management LLC acquired a new position in AbbVie in the third quarter valued at approximately $49,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Up 3.0%

ABBV stock opened at $227.57 on Friday. The firm has a market capitalization of $402.20 billion, a PE ratio of 96.43, a P/E/G ratio of 0.77 and a beta of 0.35. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock’s 50 day moving average is $223.45 and its 200-day moving average is $220.35.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the company posted $2.16 earnings per share. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales and upbeat execution: AbbVie reported record net sales and raised forward visibility after Q4 results, with analysts (e.g., Cantor Fitzgerald) reiterating bullish views and a $250 target tied to Skyrizi and Rinvoq strength. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: Korean post‑marketing Rinvoq study completed — bolsters real‑world evidence for Rinvoq in immunology, supporting long‑term revenue growth for the immunology franchise. Real‑world data can aid uptake and payer discussions. AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
• Neutral Sentiment: Analyst notes and reports are reframing valuation: recent analyst reports (Argus, other coverage) review AbbVie’s pipeline and valuation after strong results — useful for context but not a consensus catalyst. Analyst Report: AbbVie Inc
• Neutral Sentiment: Pipeline updates (elezanumab phase 2): AbbVie updated a Phase 2 study in acute cervical spinal cord injury — monitor readouts for potential long‑term upside but no immediate revenue impact. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury
• Neutral Sentiment: Small analyst PT trim from Evercore ISI: Evercore trimmed its price target modestly but kept an Outperform rating — suggests confidence in fundamentals despite nearer‑term headwinds. Evercore ISI Cuts AbbVie Inc. (ABBV) PT
• Negative Sentiment: Legal and policy risk: AbbVie sued HHS/CMS after Botox was selected for Medicare drug price negotiation under the Inflation Reduction Act — outcome could materially affect Botox pricing and margins. This litigation creates near‑term uncertainty. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Competitive pressure in immunology: J&J’s heavy Tremfya ad spend is intensifying competition for AbbVie’s Rinvoq and Skyrizi, which could pressure market share and growth trajectories in key indications. J&J’s Tremfya roars 2026 ad spend trailed by AbbVie’s Rinvoq and Skyrizi
• Negative Sentiment: U.S. operational changes and Medicaid concessions: AbbVie is reshaping U.S. operations and making Medicaid concessions to manage pricing headwinds — could weigh on near‑term U.S. margins even as it targets long‑term growth. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

Wall Street Analyst Weigh In

ABBV has been the subject of several recent analyst reports. Citigroup reduced their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Morgan Stanley boosted their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a report on Monday, November 3rd. Guggenheim raised their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Finally, DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.